Loading...
XKRX
005690
Market cap700mUSD
Dec 05, Last price  
17,190.00KRW
1D
0.76%
1Q
51.45%
Jan 2017
231.21%
Name

Pharmicell Co Ltd

Chart & Performance

D1W1MN
XKRX:005690 chart
P/E
162.92
P/S
15.91
EPS
105.51
Div Yield, %
—
Shrs. gr., 5y
0.02%
Rev. gr., 5y
14.83%
Revenues
64.85b
+15.34%
12,262,427,0008,327,605,0007,188,425,0006,368,840,00010,282,423,52011,111,800,24033,405,394,27020,155,408,36025,176,279,99027,839,155,88025,197,458,94028,351,801,13032,481,967,12037,752,047,60050,893,545,76060,181,806,97056,227,378,92564,851,304,000
Net income
6.33b
+76.95%
-907,860,000-4,432,368,000-3,953,213,000-13,832,579,000-18,172,653,000-17,642,754,530-25,700,634,600-28,768,437,020-6,390,211,570-676,712,100-39,196,611,390-12,680,884,1704,347,128,2805,241,801,2509,450,907,1608,261,768,8203,577,983,6306,331,277,000
CFO
3.50b
-70.39%
-745,665,0002,383,405,000-5,141,365,000-5,550,394,000-16,166,405,990-11,868,349,760-2,687,726,820-8,772,026,860-2,411,175,620988,968,270-2,007,324,1003,404,989,340-75,498,8808,978,054,530-5,222,199,6407,914,448,21011,814,411,6903,498,233,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to enhance the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; and Cellgram_DC, a cancer drug, as well as Hearticellgram_AM, a cardiac disease drug. It also develops and produces intermediates of raw material medicines, such as nucleosides, mPEGs, HDP-tosylate, and vincelactam; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company operates Twelve, a stem cell bank; develops and sells stem cell culture media cosmetics. Pharmicell Co., Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.
URL
http://www.pharmicell.com/
IPO date
May 20, 1988
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT